HomeNewsBusinessMarketsNifty eyes 8550, Sensex gains on pharma support; ITC, BHEL up 3%

Nifty eyes 8550, Sensex gains on pharma support; ITC, BHEL up 3%

Lupin, BHEL, ITC, SBI and Dr Reddy's Labs are top gainers while TCS, HUL, HDFC, Wipro and L&T are losers in the Sensex.

November 07, 2016 / 12:19 IST
Story continues below Advertisement

Moneycontrol Bureau11:55 am Upcoming issue: PepsiCo India's largest franchise bottling partner Varun Beverages is set to debut on the stock market on Tuesday, November 8. It has fixed issue price at Rs 445, the higher end of price band. The issue has not seen a great response from investors as high valuations and debt might have resisted investors to rethink at the time of listing. The issue, which opened for subscription during October 26-28, was oversubscribed 1.89 times on final day. It was largely supported by qualified institutional buyers, whose reserved portion oversubscribed 4.94 times whereas response from retail and high networth individuals was tepid.11:45 am Boardroom: Country's second largest public sector lender Punjab National Bank (PNB) has reported a 11.5 percent degrowth in second quarter profit at Rs 549.4 crore, impacted by higher provisions and lower NII but it was ahead of estimates due to treasury income. Asset quality also improved during the quarter but credit growth was muted. The bank said advances (loan) during the quarter grew by 3.35 percent to Rs 3.93 lakh crore and deposits increased 6.5 percent to Rs 5.74 lakh crore compared with corresponding quarter of last fiscal.

In an interview to CNBC-TV18 Usha Ananthasubramanian, MD & CEO, PNB said that the way forward is to reduce slippages.

Story continues below Advertisement

She mentioned that the NPA watchlist is dynamic as it keeps changing. The majority of the NPAs have come from one or two shipping accounts which have got classified.

11:30 am Market outlook: Midcap index has been up 23 percent since start of the financial year and there continues to be opportunities there, says Dipen Sheth of HDFC Securities. “Different themes are playing out for different midcaps,” he adds. Speaking to CNBC-TV18, Sheth says that the pharmaceutical sector has gone nowhere since the dream rally in 2014. There, however, exists potential. He is positive on Lupin and is expecting a 20 percent compounded annual growth (CAGR) over next 2-3 years on back of strong US pipeline and strong management.Don't miss: Market debut: PNB Housing Finance lists at Rs 860, up 11% over issue price